Rizatriptan for Episodic Dizziness in Vestibular Migraine
Vestibular Migraine, Migrainous Vertigo
About this trial
This is an interventional treatment trial for Vestibular Migraine
Eligibility Criteria
Inclusion Criteria: Must answer yes to be eligible
- Are between the ages of 18 & 65
- Have a history of vestibular migraine
Are able to maintain a vestibular symptom diary
History that fulfills all criteria for VM as defined in Table 1, except that attacks must last at least 2 hours.
- At least 5 episodes
- A current or past history of migraine without aura or migraine with aura
- Vestibular symptoms of moderate or severe intensity lasting at least 2 hours
50% of episodes are associated with at least one of the following:
Headache with at least 2 of:
- unilateral location
- pulsating quality
- moderate or severe intensity,
- aggravation by routine physical activity
- Experience photophobia and phonophobia
- Experience visual aura
- Episodes must have a spontaneous onset and resolution without associated hearing loss or interictal neurotologic deficits.
- Other causes of vestibular symptoms ruled out by appropriate clinical investigations.
- Current medication list compatible with Concomitant Medications below.
- Able to maintain a Vestibular Symptom Diary and complete all other study procedures.
Exclusion Criteria: Must answer no to be eligible.
- Ménière's disease by The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNS) criteria60.
- Migraine with brainstem aura (formerly basilar-type migraine) by the International Classification of Headache Disorders (ICHD-3) criteria.14
- Ischemic heart disease, coronary artery vasospasm, uncontrolled hypertension.
- History of stroke or transient ischemic attack.
- History of using rizatriptan specifically to treat vestibular attacks.
- History of adverse response to triptans or intolerance to lactose.
- Women who are pregnant or breastfeeding.
- Unable or unwilling to comply with study requirements for any reason.
Sites / Locations
- University of California, Los Angeles
- Mayo Clinic
- ICAHN School of Medicine at Mount Sinai
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo
Rizatriptan
During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.